Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12807237rdf:typepubmed:Citationlld:pubmed
pubmed-article:12807237lifeskim:mentionsumls-concept:C1140680lld:lifeskim
pubmed-article:12807237lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:12807237lifeskim:mentionsumls-concept:C0030797lld:lifeskim
pubmed-article:12807237lifeskim:mentionsumls-concept:C2347296lld:lifeskim
pubmed-article:12807237lifeskim:mentionsumls-concept:C0006610lld:lifeskim
pubmed-article:12807237lifeskim:mentionsumls-concept:C0035020lld:lifeskim
pubmed-article:12807237lifeskim:mentionsumls-concept:C0009393lld:lifeskim
pubmed-article:12807237lifeskim:mentionsumls-concept:C0554756lld:lifeskim
pubmed-article:12807237lifeskim:mentionsumls-concept:C0203418lld:lifeskim
pubmed-article:12807237pubmed:issue3-4lld:pubmed
pubmed-article:12807237pubmed:dateCreated2003-6-16lld:pubmed
pubmed-article:12807237pubmed:abstractTextFrom January 1995 to January 2001, 40 patients with epithelial ovarian cancer were treated at our Institution. Fourteen of these, with a clinical CR after surgery and platinum-based chemotherapy, were evaluated monthly by gynecological examination, Ca-125 RIA assay, pelvic ultrasound with transabdominal and transvaginal probe and color Doppler. Six pelvic relapses, from 1.5 to 3.0 cm, were detected by transvaginal ultrasound (US). They showed a rich neovascularization with low resistance, high flow, PI from 0.3 to 1.0 and RI < 0.5 in all cases. US did not reveal any sign of relapse in the remaining eight patients. In all cases of pelvic relapses ultrasonic signs of recurrence preceded the increase of Ca-125 by one to six months (average 3.8).lld:pubmed
pubmed-article:12807237pubmed:languageenglld:pubmed
pubmed-article:12807237pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12807237pubmed:citationSubsetIMlld:pubmed
pubmed-article:12807237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12807237pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12807237pubmed:statusMEDLINElld:pubmed
pubmed-article:12807237pubmed:issn0392-2936lld:pubmed
pubmed-article:12807237pubmed:authorpubmed-author:MarcyBBlld:pubmed
pubmed-article:12807237pubmed:authorpubmed-author:MoscariniMMlld:pubmed
pubmed-article:12807237pubmed:authorpubmed-author:PorzioGGlld:pubmed
pubmed-article:12807237pubmed:authorpubmed-author:CasertaDDlld:pubmed
pubmed-article:12807237pubmed:authorpubmed-author:Di RomaEElld:pubmed
pubmed-article:12807237pubmed:issnTypePrintlld:pubmed
pubmed-article:12807237pubmed:volume24lld:pubmed
pubmed-article:12807237pubmed:ownerNLMlld:pubmed
pubmed-article:12807237pubmed:authorsCompleteYlld:pubmed
pubmed-article:12807237pubmed:pagination269-70lld:pubmed
pubmed-article:12807237pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:meshHeadingpubmed-meshheading:12807237...lld:pubmed
pubmed-article:12807237pubmed:year2003lld:pubmed
pubmed-article:12807237pubmed:articleTitlePelvic relapses in ovarian cancer. Role of CA-125, transvaginal ultrasound and color Doppler.lld:pubmed
pubmed-article:12807237pubmed:affiliationDepartment of Experimental Medicine, University of L'Aquila, Italy.lld:pubmed
pubmed-article:12807237pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12807237pubmed:publicationTypeComparative Studylld:pubmed